USPTO Proposes Revisions to Patent Trial and Appeal Board Practices
Published Date: 10/17/2025
Proposed Rule
Summary
The USPTO wants to change the rules for how patent challenges happen before the Patent Trial and Appeal Board. These updates affect inventors, companies, and lawyers by making the review process clearer and possibly faster. If you want to share your thoughts, you need to comment by November 17, 2025—so don’t wait!
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
IPR Barred If Claims Were Already Found Valid
The PTAB would not institute or maintain an IPR for a challenged claim (or an independent claim from which it depends) if that claim was already found not invalid under 35 U.S.C. 102 or 103 by (1) a district court trial or jury verdict, (2) district court summary judgment, (3) the U.S. International Trade Commission, (4) a PTAB final written decision, (5) ex parte reexamination office action/Board decision, or (6) where the Federal Circuit reversed a finding of unpatentability or invalidity.
Must Promise Not To Re-raise Key Grounds
If you file an inter partes review (IPR) petition, the Board will not start or keep the IPR unless you file a written stipulation saying that, if a trial is instituted, you and any real party in interest will not raise invalidity or unpatentability grounds under 35 U.S.C. 102 or 103 in any other proceeding. That stipulation must be filed with the PTAB and any other tribunal where you are litigating regarding the challenged patent.
No IPR When Parallel Case Likely Decides First
The USPTO would not institute or maintain an IPR if, more likely than not, a parallel district court trial, an ITC initial/final determination, or a PTAB final written decision will occur with respect to the challenged claim before the PTAB's final written decision is due under 35 U.S.C. 316(a)(11).
Rule Aimed To Reduce Litigation Costs For Small Firms
The USPTO states the proposed rule focuses IPRs on patents not previously litigated or resolved early and estimates this will reduce litigation costs and transaction costs for patent licensing, likely benefiting a greater percentage of small entities. The Office certified the rule would not have a significant economic impact on a substantial number of small entities.
More PTAB Time For Ex Parte Appeals
The USPTO says limiting some IPRs will free administrative patent judge (APJ) time to handle ex parte appeals from examination, which the Office says should reduce ex parte appeal pendency and speed decisions on whether patent application claims should issue.
Paperwork Time Up 1 Hour Per Petition
The USPTO estimates each IPR petition will need one extra hour (from 120 to 121 hours) to prepare and submit the new stipulation. At 1,300 petitions per year, the Office estimates an added 1,300 annual respondent burden hours and an increase of $581,100 in hourly cost burden (using $447/hour).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2025-19557, Periodic Reporting
The Postal Service wants to change how it counts the costs of mail that can’t be delivered as addressed (UAA mail) in its regular reports. This affects anyone interested in postal costs and mail delivery, and the public can comment by November 3, 2025. These changes aim to make cost reports clearer and more accurate, but they won’t change your mailbox or prices right now.
Next: 2025-19587, Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement
The USPTO is pulling back a proposed rule that would have changed how patent challenges are handled by the Patent Trial and Appeal Board. This affects inventors, companies, and lawyers who deal with patent reviews, as the changes around multiple petitions and settlements won’t happen now. No new fees or deadlines are coming from this, but stay tuned for future updates!